Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Receivables (2016 - 2025)

Historic Receivables for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $233.9 million.

  • Collegium Pharmaceutical's Receivables rose 240.44% to $233.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.9 million, marking a year-over-year increase of 240.44%. This contributed to the annual value of $253.5 million for FY2024, which is 4122.82% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Receivables stood at $233.9 million, which was up 240.44% from $213.0 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables peaked at $253.5 million during Q4 2024, and registered a low of $90.1 million during Q2 2021.
  • Over the past 5 years, Collegium Pharmaceutical's median Receivables value was $181.9 million (recorded in 2023), while the average stood at $179.2 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Receivables soared by 11921.13% in 2022 and then crashed by 1520.27% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Receivables (Quarter) stood at $105.8 million in 2021, then soared by 73.01% to $183.1 million in 2022, then dropped by 1.96% to $179.5 million in 2023, then soared by 41.23% to $253.5 million in 2024, then decreased by 7.73% to $233.9 million in 2025.
  • Its Receivables stands at $233.9 million for Q3 2025, versus $213.0 million for Q2 2025 and $228.7 million for Q1 2025.